Di Ciano, Patricia
de Wit, Harriet
Mansouri, Esmaeil
Houle, Sylvain
Boileau, Isabelle
Le Foll, Bernard
Funding for this research was provided by:
NIH (R21DA042325-01)
Article History
Received: 18 February 2021
Accepted: 12 May 2021
First Online: 3 June 2021
Competing interests
: Dr Le Foll has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects. Dr Le Foll has some in-kind donation of cannabis product from Aurora and medication donation from Pfizer and Bioprojet and was provided a coil for TMS study from Brainsway. Dr Le Foll has obtained industry funding from Canopy (through research grants handled by CAMH or University of Toronto), Bioprojet, ACS and Alkermes. Dr Le Foll has received in kind donations of nabiximols from GW Pharma for past studies funded by CIHR and NIH. He has been consultant for Shionogi. He is supported by CAMH and a clinician-scientist award from the department of Family and Community Medicine of the University of Toronto and an Addiction Psychiatry Chair from the department of Psychiatry of the University of Toronto. The other authors declare no competing interests.